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Abstract
Benznidazole is a drug used commonly as a therapeutic agent against Chagas’ disease in Brazil. To clarify the
cytotoxic action of benznidazole the electrochemical reduction of benznidazole has been investigated using a
DNA-electrochemical biosensor, prepared by modification of a glassy carbon electrode with DNA, and the results
compared with reduction at a bare glassy carbon electrode. The dependence of peak potential with pH follows slopes
of 59 and 52 mV per pH unit in acid media, respectively, which corresponds to a mechanism involving the same
number of electrons and protons. In neutral and alkaline solution no significant dependence of peak potential with
pH was found. During the electrochemical reduction of benznidazole the formation of the hydroxylamine derivative
occurs, involving a total of four electrons. The potentials for reduction were less negative when using the
DNA-modified glassy carbon electrode than at the bare glassy carbon electrode although the mechanism was the
same, and at pH 7.51 the peak current was four times higher than that obtained with the bare electrode. The
DNA-biosensor enabled pre-concentration of the drug onto the electrode surface and the in situ damage caused to
the DNA on the electrode surface by the product of benznidazole reduction could be detected electrochemically. The
results are in agreement with the hypothesis that the hydroxylamine derivative is the reactive species responsible for
the cytotoxic action of benznidazole. © 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Nitroimidazoles are compounds that have been
used in therapeutics during the last 40 years. They
are important because they are wide-spectrum
drugs, being active against Gram-positive and
Gram-negative bacteria, protozoa, helmintes, hy-
poxic tumours, and causing a low level of resis-
tance in anaerobic microorganisms [1–4].
The first nitroimidazole with biological activity
investigated was metronidazole, showing preferen-
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tial action on Trycomoniasis aginalis [5], and
since then studies on other nitroimidazoles have
appeared [1–3]. Benznidazole (BZN) [5,6], is com-
monly used for Chagas’ disease treatment, being
the only drug marketed in Brazil [7] against this
parasitosis.
Chagas’ disease affects about one quarter of
Latin America’s population, about 100 million
people living under the risk of contracting the
parasitosis and 16–18 million people are infected
according to the World Health Organization
(WHO) [8]. In Brazil, where about 6 million peo-
ple are infected, the main problem is resistance of
T. cruzi to nifurtimox the other anti-trypanosomal
drug available. Both benznidazole and nifurtimox
are only effective in the acute phase of the disease
[7].
The biological action of nitrocompounds is de-
pendent on the reduction of the nitro group. The
nitro anionic radical and hydroxylamine deriva-
tive are the main intermediate products responsi-
ble for the cytotoxic action of the nitroimidazoles
[3,6,9]. The pharmacological properties of these
compounds have been quantitatively related to
reduction of the redox couple R–NO2/R–NO2−
and hydroxylamine formation [9,10].
Structure–activity relationship studies [11]
demonstrated that the reduction potential corre-
lates with the antimicrobial activity of nitro-hete-
rocyclic compounds. Some of these compounds
have tripanomicidal action because the
flavoproteins are able to reduce the nitrocom-
pound to the nitroradical or because of the for-
mation of superoxide and hydrogen peroxide, as a
consequence of electron transfer from the nitro-
radical to the molecular oxygen [3,4,12].
Experiments demonstrate that the products of
nitro group reduction react with nucleic acids in
vitro and it is believed that DNA is the main
target in vivo [13]. Both double helix and single-
stranded DNA suffer the action of nitroimidazole
drugs [14]; the damage to DNA depends on the
stability of the intermediate product formed on
drug reduction. The nitro anionic radical is the
species principally responsible for DNA damage,
oxidizing the DNA double helix and inducing
thymidine phosphate release [1,3]. On the other
hand, it was shown that 5-hydroxylamineimida-
zole could be the species principally responsible
for the bactericide action of the nitroimidazole
[15]. However, for 2-nitroimidazoles, such as ben-
znidazole, extensive formation of guanine adducts
across the phosphate-ester link is considered, re-
sulting from reduction of the drug and hydroxy-
lamine derivative formation [16].
The nucleic acid bases interact with the inter-
mediate generated during the nitroimidazole re-
duction [1,3,13], with preferential nitroimid-
azole–guanine interaction [13]. 5-Nitroimidazole,
metronidazole, tinidazole and secnidazole, were
studied using a DNA-biosensor, prepared by
modification of a glassy carbon electrode with
DNA [17,18]. It was possible to pre-concentrate
the drugs in the DNA layer physisorbed on the
electrode surface, which is a great advantage of
the biosensor. With pre-concentration, the
voltammogram for the cathodic peak of metron-
idazole was a high, sharp and symmetric peak,
corresponding to reduction of the nitro group to
the hydroxylamine derivative. This hydroxylamine
formed by reduction of nitroimidazoles causes in
situ damage to the DNA on the electrode surface,
which is electrochemically detected. In these ex-
perimental conditions a low detection limit of 1.0
M was obtained for metronidazole [20,21] and
this methodology showed good possibilities for
comprehension of the biological mechanism of
nitroimidazoles.
The voltammetric reduction of 5-nitroimida-
zoles using mercury [19] and solid [20,21] elec-
trodes has been investigated. The mechanism of
action of nitroimidazole as antimicrobial agent
[11], and for the analysis of pharmaceutical [22,23]
and clinical samples [22,24] was also studied
voltammetrically. However, the only published
electrochemical study of benznidazole, a 2-ni-
troimidazole, concerns its polarographic determi-
nation in dimethylsulfoxide [25].
In this paper the voltammetric behaviour of
benznidazole at a glassy carbon electrode and at a
DNA-biosensor is presented. The study of the
benznidazole–DNA interaction after in situ elec-
trochemical generation of the hydroxylamine
derivative which damages the immobilized DNA
on the glassy carbon electrode surface was possi-
ble using the DNA-biosensor.
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2. Experimental
2.1. Chemicals and solutions
Benznidazole (BZN) was supplied by Roche
Farmaceˆutica, Brasil. A 0.01 M solution of ben-
znidazole was prepared by direct dissolution in
ethanol 80% and kept at 4 °C. No chemical
changes of the analyte solution were observed
during the experiments.
Calf thymus DNA (sodium salt, type I), was
obtained from Sigma Chemical Co. and was
used without further purification. Single
stranded DNA (ss DNA) was prepared by treat-
ing an accurately weighed sample of approxi-
mately 3 mg of DNA with 0.5 ml of 60% pure
perchloric acid; after dissolution 0.5 ml of 9M
NaOH was added to neutralize the solution. The
volume was completed to 10 ml with 0.1 M pH
4.5 acetate buffer and the solution kept at 4 °C.
The pH study was performed using universal
buffer solutions prepared from a mixture of
phosphoric acid, acetic acid and boric acid with
NaOH [26]. Acetate buffer pH 4.5 with ionic
strength 0.1 M was also used as supporting elec-
trolyte. All reagents were from Merck and the
solutions were prepared using purified water
from a Millipore Milli-Q system (conductivity
0.1 S cm−1).
All experiments were carried out at room tem-
perature and in deoxygenated solution, after
bubbling nitrogen for 10 min.
2.2. Apparatus
Voltammograms were recorded using a
Autolab potentiostat/galvanostat running with
GPES version 4.1 software, from Eco-Chemie,
Utrecht, Netherlands. Differential pulse voltam-
metry conditions were: pulse amplitude 50 mV,
pulse width 70 ms and scan rate 5 mV s−1. All
experiments were performed using an electro-
chemical cell of 10 ml with a three electrode
system consisting of a glassy carbon or DNA-
modified glassy carbon electrode as working
electrode (d=3.0 mm), a platinum auxiliary
electrode and a Ag/AgCl reference electrode.
Differential pulse voltammograms were recorded
using a scan rate of 5 mV s−1, pulse amplitude
50 mV and pulse width 70 ms, while cyclic
voltammograms were recorded at scan rate of
100 mV s−1.
A Crison micropH 2001 pH meter in conjunc-
tion with a combined glass electrode from In-
gold was used for pH measurement.
2.3. DNA-biosensor
The DNA-biosensor was prepared by covering
the glassy carbon electrode with 3 mg of native
DNA dissolved in 80 l of pH 4.5 acetate
buffer. This DNA-modified glassy carbon elec-
trode was then left to dry. The DNA-modified
glassy carbon electrode was placed in the elec-
trochemical cell containing acetate buffer (pH
4.5) and conditioned at +1.4 V during 5 min.
Afterwards it was immersed in a 78 g ml−1
ssDNA solution and several differential pulse
voltammograms were recorded between 0 and
+1.4 V versus SCE to check that no electro-
chemical reaction occurs on the surface of the
DNA-modified glassy carbon electrode in sup-
porting electrolyte. This conditioning process
was repeated until stable peak currents were ob-
tained for guanine and adenine oxidation. At
this stage the DNA-biosensor reached the maxi-
mum activity for electroanalytical applications
[27], and was then dried at room temperature
and used to study the mechanism of action of
nitroimidazoles with DNA. The DNA-biosensor
prepared in this way has electroanalytical stabil-
ity during 4 days of constant use.
3. Results and discussion
The electrochemical reduction of nitroimida-
zole compounds follows a complex mechanism.
Theoretically, the nitro group can receive up to
six electrons in the complete reduction to the
amine derivative [1,3,19]. Voltammetric nitroimi-
dazole reduction indicated nitroso (R–NO) and
hydroxylamine (R–NHOH) derivative forma-
tion, involving a total of four electrons, as
shown in Scheme 1 [19].
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Scheme 1. Mechanism of reduction of benznidazole.
nitroimidazole [20,21], benznidazole reduction is
also pH-dependent in acidic medium, the reduc-
tion peak potential being shifted to negative val-
ues with increasing pH. The variation of Ep for
the reduction of benznidazole with pH, Fig. 2,
shows slopes of 59 and 52 mV per pH unit,
respectively, with the DNA-modified glassy car-
bon electrode and bare glassy carbon electrode.
This behaviour confirms proton participation in
the reduction process of benznidazole, and corre-
sponds to a mechanism involving the same num-
ber of electrons and protons. For pH values
above 7.0, no significant variation of Ep with pH
was observed and the values obtained for the
peak potentials with both types of electrode were
very close. The main reduction product is the
hydroxylamine derivative, as for metronidazole
[20,21].
For pH7.0 the peak current values for the
reduction wave of benznidazole were also shifted,
but no significant linear relationship was ob-
served. Using voltammetry the nitroimidazoles
can be reduced in only one step to the amine
derivative in alkaline medium. Under these condi-
3.1. Benznidazole reduction
Differential pulse voltammetry was used to
study the reduction of benznidazole at two differ-
ent pH values, 3.06 and 7.51, using a bare glassy
carbon electrode (curve 1) and a DNA-biosensor
(curve 2) as shown in Fig. 1. For both pHs only
one reduction wave was obtained, corresponding
to reduction of the nitro group to the hydroxy-
lamine derivative. The peak potential using the
DNA-biosensor occurs at potentials 40 and 30
mV less negative than observed at the bare glassy
carbon electrode for pH 3.06 and 7.51, respec-
tively. Additionally, at pH 7.51 the peak current
obtained at this DNA-modified glassy carbon
electrode was four times higher than that obtained
with the bare glassy carbon electrode.
In a similar way to what was observed for
Fig. 1. Differential pulse voltammograms of 50.0 mM benznidazole in universal buffer: (1) glassy carbon electrode; (2) DNA-
modified glassy carbon electrode. Scan rate 5 m V s−1.
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Fig. 2. Plot of Ep vs. pH for a solution of 50.0 mM: benznida-
zole () DNA- modified glassy carbon electrode; () glassy
carbon electrode.
the experiments benznidazole was first pre-con-
centrated from bulk solution on the DNA multi-
layer immobilised on the glassy carbon surface,
i.e. the DNA-biosensor. The pre-concentration
concentration conditions were 5 min deposition
time, td=5 min, at an applied fixed deposition
potential, Ed=−0.4 V. According to the mecha-
nism of reduction of benznidazole at this potential
on the electrode surface in situ formation of the
hydroxylamine derivative occurs, Fig. 1, which
reacts with the DNA in the biosensor and is
responsible for the damage caused to DNA. The
deposition time used has already been optimised
[17].
The DNA–benznidazole interaction was fol-
lowed by cyclic and differential pulse
voltammetry.
The cyclic voltammograms, Fig. 3, show four
very well-defined peaks: Ep,Ia=+0.26 V; Ep,Ic=
+0.17 V; Ep,II=+0.60 V and Ep,III=−0.37 V.
The peaks Ia and Ic can be attributed to the
reversible hydroxylamine/nitroso derivative cou-
ple [17,18], product of voltammetric reduction of
benznidazole, according to the chemical
equilibrium
tions it was not possible to distinguish the full
six-electron reduction of benznidazole [25].
The results obtained for the benznidazole re-
duction using a DNA-biosensor demostrate good
possibilities for developing an electronalytical
methodology for benznidazole determination.
However, in the case of this work the objective
was the use of the voltammetric methods for the
study of the biological mechanism of benznida-
zole–DNA interaction and of the structure–activ-
ity relationship, which can be an important
parameter in structure–activity studies.
3.2. Benznidazole–DNA interaction
The reduction mechanism using the DNA-
biosensor or the bare glassy carbon electrode is
the same. However, the significant increase in
peak current due to pre-concentration of the
DNA matrix on the electrode surface of benznida-
zole enables larger peak currents to be obtained
and thus permits more easily the study of DNA–
benznidazole interaction.
For the purpose of studying DNA-benznidazole
interaction the procedure was as follows. During
Fig. 3. Cyclic voltammogram of 0.43 mM benznidazole ob-
tained with the DNA-modified glassy carbon electrode in pH
4.5 0.1 M acetate buffer solution. Scan rate 100 mV s−1,
Ed=−0.4 V, td=5 min and Ei=−0.2 V.
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R−NHOH 
Ia
Ic
R−NO+2e+2H+
Peak II can be identified as the possible interac-
tion between the benznidazole reduction products
and DNA immobilised on the electrode surface.
The characterisation of this peak was based on
previous results [17,18] and on literature data that
presents the purine bases [13] as the main target
of nitroimidazole drugs for oxidative damage to
DNA. According to Dryhust [28], oxidation prod-
ucts of purine bases have anodic peaks around 0.5
V. Based on his findings, peak II would corre-
spond to deoxypurinic acid oxidation, for exam-
ple 8-oxoguanine [29]. The deoxypurinic acid is
formed as a consequence of the action of the
products of benznidazole reduction on the DNA
immobilised on the electrode surface. Peak III
corresponds to the four electron benznidazole re-
duction studied in the previous section.
The benznidazole–DNA interaction was more
fully investigated by differential pulse voltamme-
try. Differential pulse voltammograms, Fig. 4,
show two very well-defined peaks: Ep,Ia=+0.20
V and Ep,II=+0.53 V and several smaller oxida-
tion peaks, the size of which increase with ben-
znidazole concentration.
Because the voltammetric behaviour of nitroim-
idazoles and their interactions with DNA bases
had previously been studied using mercury elec-
trodes [13,19,25,30], it was not possible due to the
mercury electrode to investigate the anodic re-
gion. The use of the DNA-biosensor allowed the
anodic voltammetric study of nitroimidazoles and
led to an explanation for the differences in reac-
tivity between 5-nitroimidazoles and 2-nitroimida-
zoles. The results obtained with benznidazole are
quite different to those obtained with metronida-
zole [17,18]. In the latter, a well-defined peak was
observed at +0.224 V and attributed to an
azoxycompound formed during the condensation
reaction between hydroxylamine and its nitroso
derivative at the electrode surface. The amount of
azoxycompound formed depends on the concen-
tration of the nitroso derivative, which is reduced
rapidly to hydroxylamine [17]. Nevertheless, for-
mation of this compound was not observed dur-
ing the anodic scan of benznidazole. It seems that
the hydroxylamine derivative-DNA interaction
Fig. 4. Differential pulse voltammograms of benznidazole
obtained with the DNA-modified glassy carbon electrode in
pH 4.5 0.1 M acetate buffer: 1, 0.050 mM; 2, 1.50 mM; 3, 43.0
mM; s.e.—supporting electrolyte. Scan rate 5 mV s−1, Ed=
−0.4 V, td=5 min and Ei=−0.2 V.
was sufficiently fast and efficient to avoid the
condensation reaction. This result corroborates
the hypothesis that the hydroxylamine derivatives
of 2-nitroimidazoles are the reactive species re-
sponsible for cytotoxic drug action [15,16].
The smaller oxidation peaks can be identified
with the oxidation of the purine nucleotides
guanosine (Ep,a=+1.05 V) and adenosine
(Ep,a=+1.20 V), caused by the DNA–benznida-
zole interaction.
The effect of drug concentration on the peak
currents of Ep,I and Ep,II is shown in Fig. 5.
Standard addition of benznidazole caused an in-
crease in current values for the two peaks. The
current for peak I, corresponding to hydroxy-
lamine oxidation, reaches a plateau. This can be
explained by saturation of the DNA immobilised
on the glassy carbon electrode. For the second
peak, the current varies linearly with benznidazole
concentration, in spite of a less significant increase
of current with concentration increment.
M.A. La-Scalea et al. / J. Pharm. Biomed. Anal. 29 (2002) 561–568 567
Fig. 5. Standard addition curves of benznidazole from differ-
ential pulse voltammograms obtained with the DNA-modified
glassy carbon electrode in pH 4.5 0.1 M acetate buffer: ()
peak Ia (Ep=+0.18 V); () peak II (Ep=+0.55 V). Scan
rate 5 m V s−1, Ed=−0.4 V, td=5 min and Ei=−0.2 V.
These results also aid in understanding the
mechanism of action of nitroimidazoles and ex-
plain the differences in reactivity between differ-
ent nitroimidazoles. They can be used as
important parameters for quantitative studies of
structure–activity relationships (QSAR), and as a
contribution to the design of new candidates to
drugs.
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